Drug Profile

L2 P4

Alternative Names: L-2P4

Latest Information Update: 28 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hong Kong Baptist University
Class Antineoplastics; Antivenins; Peptide drug conjugates; Small molecules
Mechanism of Action Epstein Barr virus replication inhibitors; Epstein-Barr virus nuclear antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jun 2024 No recent reports of development identified for preclinical development in Nasopharyngeal-cancer in Hong Kong (Parenteral, Injection)
02 Mar 2021 Pharmacodynamics data from preclinical studies in Nasopharyngeal cancer released by Hong Kong Baptist University
02 Mar 2021 Hong Kong Baptist University in collaboration with BP InnoMed plans a clinical trial in Nasopharyngeal cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com